The Type I Interferon Signaling Pathway Is a Target for Glucocorticoid Inhibition
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Type I interferon (IFN) is essential for host defenses against viruses; however, dysregulated IFN signaling is causally linked to autoimmunity, particularly systemic lupus erythematosus. Autoimmune disease treatments rely on glucocorticoids (GCs), which act via the GC receptor (GR) to repress proinflammatory cytokine gene transcription. Conversely, cytokine signaling through cognate Jak/STAT pathways is reportedly unaffected or even stimulated by GR. Unexpectedly, we found that GR dramatically inhibited IFN-stimulated gene (ISG) expression in macrophages. The target of inhibition, the heterotrimeric STAT1-STAT2-IRF9 (ISGF3) transcription complex, utilized the GR cofactor GRIP1/TIF2 as a coactivator. Consequently, GRIP1 knockdown, genetic ablation, or depletion by GC-activated GR attenuated ISGF3 promoter occupancy, preinitiation complex assembly, and ISG expression. Furthermore, this regulatory loop was restricted to cell types such as macrophages expressing the GRIP1 protein at extremely low levels, and pharmacological disruption of the GR-GRIP1 interaction or transient introduction of GRIP1 restored RNA polymerase recruitment to target ISGs and the subsequent IFN response. Thus, type I IFN is a cytokine uniquely controlled by GR at the levels of not only production but also signaling through antagonism with the ISGF3 effector function, revealing a novel facet of the immunosuppressive properties of GCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Bledsoe, R. K., Montana, V. G., Stanley, T. B., Delves, C. J., Apolito, C. J., McKee, D. D., Consler, T. G., Parks, D. J., Stewart, E. L., Willson, T. M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00817-6 · Cited by 818
Functional interactions between Stat5 and the glucocorticoid receptor
Stöcklin, E., Wissler, M., Gouilleux, F., & Groner, B. (1996) · Nature · doi:10.1038/383726a0 · Cited by 675 · cited 3×
“It has been shown that GR synergizes with prolactin-activated STAT5 and with interleukin 6 (IL-6)-activated STAT3 (34, 36, 54); however, the mechanisms of synergy are unclear.”
BackgroundDNA binding site sequence directs glucocorticoid receptor structure and activity
Meijsing, S. H., Pufall, M. A., So, A. Y., Bates, D. L., Chen, L., & Yamamoto, K. R. (2009) · Science · doi:10.1126/science.1164265 · Cited by 673 · cited 1×
“Remarkably, a single-base-pair substitution in a GRE leads to changes in GR structure, activity, and the composition of the associated coactivator complexes (44, 53).”
BackgroundMolecular determinants of crosstalk between nuclear receptors and toll-like receptors
Ogawa, S., Lozach, J., Benner, C., Pascual, G., Tangirala, R. K., Westin, S., Hoffmann, A., Subramaniam, S., David, M., Rosenfeld, M. G., et al. (2005) · Cell · doi:10.1016/j.cell.2005.06.029 · Cited by 647
Self-citationCooperation of Stat2 and p300/CBP in signalling induced by interferon-α
Bhattacharya, S., Eckner, R., Grossman, S., Oldread, E., Arany, Z., D'Andrea, A., & Livingston, D. M. (1996) · Nature · doi:10.1038/383344a0 · Cited by 493
Abraham, S. M., Lawrence, T., Kleiman, A., Warden, P., Medghalchi, M., Tuckermann, J., Saklatvala, J., & Clark, A. R. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060336 · Cited by 430
Minireview: Latest Perspectives on Antiinflammatory Actions of Glucocorticoids
De Bosscher, K., & Haegeman, G. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0283 · Cited by 284
The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression
Reily, M. M., Pantoja, C., Hu, X., Chinenov, Y., & Rogatsky, I. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7600919 · Cited by 149
Self-citation
Cited by
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
Self-citationRepurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
WHO Solidarity Trial Consortium (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023184 · Cited by 2,745
Ratman, D., Vanden Berghe, W., Dejager, L., Libert, C., Tavernier, J., Beck, I. M., & De Bosscher, K. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.12.014 · Cited by 411
“for ISGF3 (Flammer et al., 2010).”
Regulating IRFs in IFN Driven Disease
Jefferies, C. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00325 · Cited by 365
Davoudi-Monfared, E., Rahmani, H., Khalili, H., Hajiabdolbaghi, M., Salehi, M., Abbasian, L., Kazemzadeh, H., & Yekaninejad, M. S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-20 · Cited by 306
Metadata
- Authors
- Flammer, J. R., Dobrovolna, J., Kennedy, M. A., Chinenov, Y., Glass, C. K., Ivashkiv, L. B., & Rogatsky, I.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2010-10-01
- Volume
- 30
- Issue
- 19
- Pages
- 4564-4574
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2102521464
- Cited by
- 136
- References
- 11
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Type I Interferon Signaling Pathway Is a Target for Glucocorticoid Inhibition. https://app.cochat.ai/papers/10.1128/mcb.00146-10
- The paper
- Flammer, J. R., Dobrovolna, J., Kennedy, M. A., Chinenov, Y., Glass, C. K., Ivashkiv, L. B., & Rogatsky, I. (2010). The Type I Interferon Signaling Pathway Is a Target for Glucocorticoid Inhibition. Molecular and Cellular Biology. https://doi.org/10.1128/mcb.00146-10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.